$BTAX
Biostax Corp.

2023 Q2 Form 10-Q Financial Statement

#000149315223016620 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $248.9K $207.5K $181.6K
YoY Change -14.8% 14.26% 30.92%
% of Gross Profit
Research & Development $175.2K $180.9K
YoY Change
% of Gross Profit
Depreciation & Amortization $13.37K $13.38K
YoY Change
% of Gross Profit
Operating Expenses $437.5K $401.8K $0.00
YoY Change 49.76% -100.0%
Operating Profit -$437.5K -$401.8K -$181.6K
YoY Change 49.76% 121.25%
Interest Expense $66.76K $14.30K -$92.18K
YoY Change 1618.46% -115.51% -108.55%
% of Operating Profit
Other Income/Expense, Net -$66.76K -$14.30K -$2.283M
YoY Change -103.2% -99.37%
Pretax Income -$504.2K -$416.1K -$2.557M
YoY Change -128.12% -83.72% -423.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$504.2K -$416.1K -$2.557M
YoY Change -128.12% -83.72% -423.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 $0.00 -$5.29
Diluted Earnings Per Share $0.00 $0.00 -$5.285M
COMMON SHARES
Basic Shares Outstanding 83.30M shares 83.30M shares 483.7K shares
Diluted Shares Outstanding 83.29M shares 83.24M shares 483.7K shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.43K $34.99K $799.1K
YoY Change -93.58% -95.62% 6753.69%
Cash & Equivalents $17.43K $34.99K $436.9K
Short-Term Investments $362.3K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.43K $34.99K $799.1K
YoY Change -93.58% -95.62% 6753.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.500K $12.61K
YoY Change
Total Long-Term Assets $741.2K $761.7K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $17.43K $34.99K $799.1K
Total Long-Term Assets $741.2K $761.7K $0.00
Total Assets $758.7K $796.7K $799.1K
YoY Change 179.4% -0.3% 6609.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.360M $1.300M $2.171M
YoY Change -5.02% -40.1% -19.91%
Accrued Expenses $136.1K $151.1K $4.366M
YoY Change -55.76% -96.54% 0.38%
Deferred Revenue
YoY Change
Short-Term Debt $1.747M $1.288M $4.052M
YoY Change -22.63% -68.2% 9.62%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.861M $3.576M $11.30M
YoY Change -43.56% -68.36% 5.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.861M $3.576M $11.30M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.861M $3.576M $11.30M
YoY Change -43.56% -68.36% 5.1%
SHAREHOLDERS EQUITY
Retained Earnings -$383.9M -$383.4M
YoY Change 0.97%
Common Stock $380.8M $380.6M
YoY Change 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.102M -$2.780M -$10.87M
YoY Change
Total Liabilities & Shareholders Equity $758.7K $796.7K $799.1K
YoY Change 179.4% -0.3% 6609.82%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$504.2K -$416.1K -$2.557M
YoY Change -128.12% -83.72% -423.45%
Depreciation, Depletion And Amortization $13.37K $13.38K
YoY Change
Cash From Operating Activities -$314.0K -$265.5K -$57.00K
YoY Change -37.67% 365.79% -3472.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 296.5K $150.0K
YoY Change -12.4%
NET CHANGE
Cash From Operating Activities -314.0K -$265.5K -57.00K
Cash From Investing Activities
Cash From Financing Activities 296.5K $150.0K
Net Change In Cash -17.57K -$115.5K -57.00K
YoY Change -89.37% 102.63% -3472.78%
FREE CASH FLOW
Cash From Operating Activities -$314.0K -$265.5K -$57.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001559356
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023Q1 IMUN Decrease In Carrying Value Of Common Shares
DecreaseInCarryingValueOfCommonShares
usd
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
usd
CY2022Q1 IMUN Common Stock Issued For Extension Of Patent And License Agreement
CommonStockIssuedForExtensionOfPatentAndLicenseAgreement
usd
CY2022Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2023Q1 IMUN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
CY2023Q1 IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q1 IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
CY2023Q1 IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-54933
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
IMMUNE THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3226705
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2431 Aloma Ave.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 124
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Winter Park
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32792
CY2023Q1 dei City Area Code
CityAreaCode
888
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
613-8802
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83295857 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34993 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150491 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
34993 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
150491 usd
CY2023Q1 IMUN Patents And Licenses
PatentsAndLicenses
749123 usd
CY2022Q4 IMUN Patents And Licenses
PatentsAndLicenses
762500 usd
CY2023Q1 us-gaap Deposits Assets
DepositsAssets
12612 usd
CY2022Q4 us-gaap Deposits Assets
DepositsAssets
50728 usd
CY2023Q1 us-gaap Assets
Assets
796728 usd
CY2022Q4 us-gaap Assets
Assets
963719 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1300366 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1300366 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
336002 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
336002 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
846478 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
696478 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
441868 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
394736 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
78754 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
64455 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
151057 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
136057 usd
CY2023Q1 IMUN License Fees Payable Current
LicenseFeesPayableCurrent
421774 usd
CY2022Q4 IMUN License Fees Payable Current
LicenseFeesPayableCurrent
549079 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3576299 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3477173 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3576299 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3477173 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83295857 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83295857 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83045857 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83045857 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8330 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8305 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380586407 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380436432 usd
CY2023Q1 IMUN Stock Issuances Due
StockIssuancesDue
10303 usd
CY2022Q4 IMUN Stock Issuances Due
StockIssuancesDue
10303 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383384611 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-382968494 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2779571 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2513454 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
796728 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
963719 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
207517 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
181616 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180924 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13377 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
401818 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
181616 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-401818 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-181616 usd
CY2022Q1 IMUN Decrease In Carrying Value Of Common Shares
DecreaseInCarryingValueOfCommonShares
-2282750 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
14299 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
92184 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14299 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2374934 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-416117 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2556550 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83243079 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
483714 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83243079 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
483714 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7948256 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2556550 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10867056 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2513454 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2513454 usd
CY2023Q1 IMUN Stock Issued During Period Value Issued For Extension Of Patent And License Agreement
StockIssuedDuringPeriodValueIssuedForExtensionOfPatentAndLicenseAgreement
150000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-416117 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2779571 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2779571 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-416117 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2556550 usd
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2282750 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13377 usd
CY2023Q1 IMUN Common Stock Issued For Extension Of Patent And License Agreement
CommonStockIssuedForExtensionOfPatentAndLicenseAgreement
150000 usd
CY2023Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-38116 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13828 usd
CY2023Q1 IMUN Increase Decrease In License Fees Payable
IncreaseDecreaseInLicenseFeesPayable
-127305 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
4620 usd
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
14299 usd
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
92184 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
43826 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
47132 usd
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
90001 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-265498 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56997 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
150000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-115498 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56997 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150491 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
493885 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34993 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
436888 usd
CY2023Q1 us-gaap Cash
Cash
34993 usd
CY2023Q1 IMUN Working Capital
WorkingCapital
3541306 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383384611 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-416117 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2556550 usd
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2282750 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_ziowqbC5Oi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zcYCl9CvZ5vl">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34993 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150491 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zp9Zc59QFfXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zZaHPD6mFkZc">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zWVPakr9DZD" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180924 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-416117 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2556550 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83243079 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
483714 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-416117 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2556550 usd
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83243079 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
483714 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
846478 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
696478 usd
CY2023Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
78754 usd
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
64455 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
34495 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
38495 shares
CY2022Q4 IMUN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice
59.42
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
4000 shares
CY2023Q1 IMUN Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice
32.50
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
34495 shares
CY2023Q1 IMUN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice
62.54
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-23-016620-index-headers.html Edgar Link pending
0001493152-23-016620-index.html Edgar Link pending
0001493152-23-016620.txt Edgar Link pending
0001493152-23-016620-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
imun-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
imun-20230331_cal.xml Edgar Link unprocessable
imun-20230331_def.xml Edgar Link unprocessable
imun-20230331_lab.xml Edgar Link unprocessable
imun-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending